You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: October 3, 2023

Patent: 10,172,905

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,172,905
Title:Treatment of protein degradation disorders
Abstract: The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to methods and pharmaceutical compositions for treating multiple myeloma. New HDAC/TDAC inhibitors and aggresome inhibitors are also provided as well as synthetic methodologies for preparing these compounds.
Inventor(s): Anderson; Kenneth C. (Wellesley, MA), Bradner; James E. (Weston, MA), Greenberg; Edward Franklin (Cleveland, OH), Hideshima; Teru (Brookline, MA), Kwiatkowski; Nicholas Paul (Brookline, MA), Mazitschek; Ralph (Belmont, MA), Schreiber; Stuart L. (Boston, MA), Shaw; Jared (Davis, CA), Haggarty; Stephen J. (Gloucester, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA) Dana-Farber Cancer Institute, Inc. (Boston, MA)
Application Number:15/401,902
Patent Claims:see list of patent claims

Details for Patent 10,172,905

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2025-03-22
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2025-03-22
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2025-03-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.